These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 29447015)
21. The multicellular tumor spheroid model for high-throughput cancer drug discovery. LaBarbera DV; Reid BG; Yoo BH Expert Opin Drug Discov; 2012 Sep; 7(9):819-30. PubMed ID: 22788761 [TBL] [Abstract][Full Text] [Related]
22. Transcriptome modeling and phenotypic assays for cancer precision medicine. Jeong E; Moon SU; Song M; Yoon S Arch Pharm Res; 2017 Aug; 40(8):906-914. PubMed ID: 28766239 [TBL] [Abstract][Full Text] [Related]
23. A new approach to assess drug sensitivity in cells for novel drug discovery. Mazzarella L; Curigliano G Expert Opin Drug Discov; 2018 Apr; 13(4):339-346. PubMed ID: 29415581 [TBL] [Abstract][Full Text] [Related]
25. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy. Amoedo ND; Obre E; Rossignol R Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330 [TBL] [Abstract][Full Text] [Related]
26. Network and systems biology: essential steps in virtualising drug discovery and development. Wierling C; Kessler T; Ogilvie LA; Lange BM; Yaspo ML; Lehrach H Drug Discov Today Technol; 2015 Aug; 15():33-40. PubMed ID: 26464088 [TBL] [Abstract][Full Text] [Related]
27. Challenges with biomarkers in cancer drug discovery and development. Ileana Dumbrava E; Meric-Bernstam F; Yap TA Expert Opin Drug Discov; 2018 Aug; 13(8):685-690. PubMed ID: 29792354 [No Abstract] [Full Text] [Related]
28. Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity. Tan P; He L; Han G; Zhou Y Trends Biotechnol; 2017 Mar; 35(3):215-226. PubMed ID: 27692897 [TBL] [Abstract][Full Text] [Related]
29. Strategy of Daiichi Sankyo discovery research in oncology. Akahane K; Hirokawa K Jpn J Clin Oncol; 2014 Feb; 44(2):109-15. PubMed ID: 24459194 [TBL] [Abstract][Full Text] [Related]
30. OptoBase: A Web Platform for Molecular Optogenetics. Kolar K; Knobloch C; Stork H; Žnidarič M; Weber W ACS Synth Biol; 2018 Jul; 7(7):1825-1828. PubMed ID: 29913065 [TBL] [Abstract][Full Text] [Related]
31. Current mathematical models for cancer drug discovery. Carrara L; Lavezzi SM; Borella E; De Nicolao G; Magni P; Poggesi I Expert Opin Drug Discov; 2017 Aug; 12(8):785-799. PubMed ID: 28595492 [TBL] [Abstract][Full Text] [Related]
32. Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic? Roukos DH Expert Rev Proteomics; 2012 Aug; 9(4):349-53. PubMed ID: 22967071 [No Abstract] [Full Text] [Related]
33. Functional protein micropatterning for drug design and discovery. You C; Piehler J Expert Opin Drug Discov; 2016; 11(1):105-19. PubMed ID: 26624534 [TBL] [Abstract][Full Text] [Related]
34. Optogenetics: Therapeutic spark in neuropathic pain. Liu K; Wang L Bosn J Basic Med Sci; 2019 Nov; 19(4):321-327. PubMed ID: 30995901 [TBL] [Abstract][Full Text] [Related]
35. Identification of disease-relevant genes for molecularly-targeted drug discovery. Kauselmann G; Dopazo A; Link W Curr Cancer Drug Targets; 2012 Jan; 12(1):1-13. PubMed ID: 22165964 [TBL] [Abstract][Full Text] [Related]
36. Cancer drug discovery: recent innovative approaches to tumor modeling. Lovitt CJ; Shelper TB; Avery VM Expert Opin Drug Discov; 2016 Sep; 11(9):885-94. PubMed ID: 27454169 [TBL] [Abstract][Full Text] [Related]
37. Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done? Witkowska M; Smolewski P; Majchrzak A; Robak T Expert Opin Drug Discov; 2016 Nov; 11(11):1033-1045. PubMed ID: 27569454 [TBL] [Abstract][Full Text] [Related]